EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Kynurenine pathway metabolite alterations in Down syndrome and Alzheimer's disease

Rafaela Gomes Dos Reis, Monique Patricio Singulani, Orestes Vicente Forlenza, Wagner Farid Gattaz, Leda Leme Talib iD

Alzheimer's & Dementia · 2025-05 · 21 (5)

DOI: 10.1002/alz.70197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 21.05.2025. Verfasst von Rafaela Gomes Dos Reis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neuroscience (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas da Faculdade de Medicina da Universidade de São P…. Hauptthemen laut MEDLINE: Down Syndrome, Alzheimer Disease, Kynurenine. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto Nacional de Biomarcadores em Neuropsiquiatria, Programa Nacional de Apoio à Atenção da Saúde da Pessoa com Deficiência, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Down syndrome (DS) is a genetic disorder that leads to intellectual disability and accelerated aging, increasing the risk of Alzheimer's disease (AD). The pathophysiology of AD and DS is multifactorial, involving amyloid precursor protein overexpression, neuroinflammation, and oxidative stress. This study investigates kynurenine pathway metabolites in elderly individuals with DS (with/without cognitive decline), AD, and cognitively healthy controls to clarify their roles in these pathogeneses. METHODS A cross‐sectional study was conducted involving DS, AD, and healthy participants. Plasma levels of tryptophan, kynurenine, 3‐hydroxykynurenine, anthranilic acid, 3‐hydroxyanthranilic acid, and quinolinic acid were analyzed by Liquid Chromatography coupled with Tandem Mass spectrometry (LC‐MS/MS) methodology. RESULTS Elevated kynurenine and other neuroprotective metabolites were found in DS individuals without cognitive decline, while significant differences in neurotoxic metabolites were observed between groups. DISCUSSION Our findings suggest a link between kynurenine pathway dysregulation and cognitive decline, indicating alterations in DS and AD. Highlights There are altered kynurenine pathway metabolites in Down syndrome and Alzheimer's disease. Elevated neuroprotective metabolites are found in Down syndrome without cognitive decline. Significant differences in neurotoxic metabolites among study groups were analyzed. There is a potential link between kynurenine pathway dysregulation and cognitive decline. The study provides insights into metabolic changes in aging and neurodegeneration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromeAlzheimer DiseaseKynurenineHumansMaleFemaleAgedCross-Sectional StudiesMiddle AgedTryptophanortho-AminobenzoatesChromatography, LiquidTandem Mass SpectrometryQuinolinic AcidCognitive Dysfunction3-Hydroxyanthranilic Acid

Stichwörter der Autor:innen

Alzheimer's diseaseDown syndromecognitive declinekynurenine pathwayplasma biomarkers

Substanzen

KynurenineTryptophan3-hydroxykynurenineanthranilic acidortho-AminobenzoatesQuinolinic Acid3-Hydroxyanthranilic Acid

Autor:innen und Institutionen

  • Laboratory of Neuroscience (LIM-27), Departamento e Instituto de Psiquiatria, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil.
  • Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN), Conselho Nacional de Desenvolvimento Científico e Tecnológico, São Paulo, São Paulo, Brazil.
  • Centro de Neurociências Translacionais (CNT), Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil.

ORCID-Profile: Leda Leme Talib

Förderung

  • Instituto Nacional de Biomarcadores em Neuropsiquiatria
  • Programa Nacional de Apoio à Atenção da Saúde da Pessoa com Deficiência
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Dos Reis, R. G., Singulani, M. P., Forlenza, O. V., Gattaz, W. F., & Talib, L. L. (2025). Kynurenine pathway metabolite alterations in Down syndrome and Alzheimer's disease. Alzheimer's & Dementia, 21(5). https://doi.org/10.1002/alz.70197

Vancouver

Dos Reis RG, Singulani MP, Forlenza OV, Gattaz WF, Talib LL. Kynurenine pathway metabolite alterations in Down syndrome and Alzheimer's disease. Alzheimer's & Dementia. 2025;21(5). doi:10.1002/alz.70197

BibTeX
@article{DosReis2025,
  author = {Dos Reis, Rafaela Gomes and Singulani, Monique Patricio and Forlenza, Orestes Vicente and Gattaz, Wagner Farid and Talib, Leda Leme},
  title = {Kynurenine pathway metabolite alterations in Down syndrome and Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {5},
  doi = {10.1002/alz.70197}
}
Kostenlos starten →